Regional News Archives - Page 156 of 189 - Journal for Clinical Studies

Current Edition

Europe

Orion’s and Bayer’s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019: Orion's and Bayer's darolutamide plus androgen deprivation therapy (A...

20 February 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

New Clinerion And Citeline Partnership Simplifies and Strengthens Matchmaking Between Clinical Researchers and Qualified Patients

Collaboration between two companies leads to more informed decisions for clinical researchers, grounded in real-world evidence. Citeline, part of the Informa Pharm...

20 February 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

Our brains indicate how well depression will respond to treatment

(Vienna, 19 February 2019) Working with international partners, a MedUni Vienna research group has shown that imaging techniques carried out prior to treatment indic...

20 February 2019 Europe | news | Regional News

Continue Reading →

Europe

AlzProtect, on Track for a Phase 2 Entry in 2019, for its Drug Candidate AZP2006

LILLE, France, February 20, 2019 --AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease and Progressi...

20 February 2019 Europe | news | Regional News

Continue Reading →

news

Despite Phase III failure, Gilead’s selonsertib may still have place in NASH combination therapy strategy, says GlobalData

Despite its failure in the Phase III STELLAR-4 trial, Gilead Sciences’ lead non-alcoholic steatohepatitis (NASH) drug candidate, selonsertib, may still have a pla...

20 February 2019 news | North America | Regional News

Continue Reading →

Asia Pacific

Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China

Cambridge, UK, and Shanghai, China, February 20 2019: Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in ea...

20 February 2019 Asia Pacific | news | Regional News

Continue Reading →

Europe

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

Merck & Co. said Thursday it plans to launch three pivotal Phase 3 studies testing different combination therapies involving its blockbuster immunotherapy Keytru...

20 February 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

Merck’s Keytruda set to become new standard of care for renal cancer patient population after gaining edge over competitors, says GlobalData

Merck & Co Inc’s abstract presentation regarding KEYNOTE-426 trial at ASCO GU 2019 (16 February 2019) has confirmed that Keytruda, an anti-PD-1 therapy, in combi...

20 February 2019 Europe | news | North America | Regional News

Continue Reading →

news

Approving J&J’s new depression drug would be an unusual move for the FDA

The Food and Drug Administration would be making an unusual move if it greenlights Johnson & Johnson's experimental depression treatment, according to a briefing...

14 February 2019 news | North America | Regional News

Continue Reading →

news

Merck kidney cancer data impresses, putting pressure on Bristol-Myers

Better-than-expected positive results from a late-stage study could position Merck & Co's immunotherapy Keytruda to play a large role in the treatment of metasta...

14 February 2019 news | North America | Regional News

Continue Reading →